RxDoctor Payments Data

Kora Smith, OD

Optometrist · Indianapolis, INNPI 1063908929

Payments from drug & device makers

$3,011in general payments, 2019–2025

Across 109 payments — averaging $27.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tarsus Pharmaceuticals, Inc.$527
  • Mallinckrodt Hospital Products Inc.$497
  • AbbVie$347
  • Sun Pharmaceutical Industries Inc.$286
  • Alcon$280
  • Kala Pharmaceuticals, Inc.$265
  • plus $810 from 12 others

What the payments were for

  • Food & beverage$2,81293%
  • Education$2007%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,011 in reported general payments places this provider in the 85th percentile of 1,318 optometrist providers in Indiana.

See all optometrist providers in Indiana

Medicare billing

Part B allowed, 2024
$98,409
Medicare patients
320
Services billed
1,466

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine101$90,230
LumiganBimatoprost85$41,331
XiidraLifitegrast28$34,270
RocklatanNetarsudil Mesylat/Latanoprost22$19,906
CequaCyclosporine27$16,796
SimbrinzaBrinzolamide/Brimonidine Tart43$10,070
Cyclosporine14$4,266
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol32$2,300
Latanoprost289$2,243
Prednisolone Acetate46$1,270
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat43$1,156
Brimonidine Tartrate106$853
Timolol Maleate82$548
Dorzolamide Hcl19$212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$347$131,561186 claims
Bausch & Lomb Americas Inc.Xiidra$141$34,27028 claims
Aerie Pharmaceuticals, Inc.Rocklatan$24$19,90622 claims
Sun Pharmaceutical Industries Inc.Cequa$286$16,79627 claims
AlconSimbrinza$280$10,07043 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,318 optometrist providers in Indiana.

Other optometrist in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →